clinical trial

[MRM Health] MRM Health announced that the first patient received MH002 in a Phase Ib/IIa multi-center clinical trial in mild-to-moderate ulcerative colitis.

[SOTIO Biotech] SOTIO Biotech announced that it has entered into a clinical trial collaboration and supply agreement with MSD to evaluate the combination of SOT101, SOTIO’s IL-15 superagonist, and MSD’s KEYTRUDA® in patients with selected advanced/refractory solid tumors in the Phase II AURELIO-04 study.

[NOXXON Pharma N.V.] NOXXON Pharma N.V. announced that the first patient was enrolled in an expansion arm of the GLORIA clinical trial of NOX-A12 in MGMT unmethylated brain cancer.

[QSAM Biosciences, Inc.] QSAM Biosciences, Inc. announced the activation of its first clinical trial site and the initiation of enrollment of patients into its Phase I clinical trial evaluating CycloSam® for multiple types of bone cancer that either originated in or has metastasized to the bone.

[Nature Reviews Gastroenterology & Hepatology] Scentists present the state of the art on the most recently identified pathogenic mechanisms of this serious inflammatory bowel disease-related complication, focusing on possible targets of antifibrotic therapies, management strategies, and factors that might predict fibrosis progression or response to treatment.

[PDS Biotechnology Corporation] PDS Biotechnology Corporation announced the reopening of recruitment in the National Cancer Institute-led Phase II clinical trial evaluating PDS0101 in combination with two investigational immune-modulating agents in advanced HPV cancers.